The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Diagnostic Exosome Biomarker Market Research Report 2025
Synopsis
The fusion of plasma membrane with the internal vesicle fusion leads to the secretion of nanovescicles called exosomes into the extracellular environment. The exosomes are released in easily accessible body fluids such as urine and blood and hence acts as a precious source of biomedical tool. As cancer is a booming research area, exosomes may act as a very useful biomarkers for the diagnosis and prognosis of malignant tumor. The application of exosome as a potential biomarker for the various neurodegenerative disorders is also under investigation.
The global Diagnostic Exosome Biomarker market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Diagnostic Exosome Biomarker, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diagnostic Exosome Biomarker.
Report Scope
The Diagnostic Exosome Biomarker market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Diagnostic Exosome Biomarker market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diagnostic Exosome Biomarker companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
101Bio
AMS Biotechnology
BioRegenerative Sciences
Cell Guidance Systems
Codiak BioSciences
Evomic Science
ExoCyte Therapeutics
Bio-Techne
Exovita biosciences
Immune Therapy Holdings
Lonza
Norgen Biotek
ReNeuron Group
Therapeutic Solutions International
Segment by Type
Membrane-bound Proteins
Soluble Proteins
Noncoding RNA
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Diagnostic Exosome Biomarker companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The fusion of plasma membrane with the internal vesicle fusion leads to the secretion of nanovescicles called exosomes into the extracellular environment. The exosomes are released in easily accessible body fluids such as urine and blood and hence acts as a precious source of biomedical tool. As cancer is a booming research area, exosomes may act as a very useful biomarkers for the diagnosis and prognosis of malignant tumor. The application of exosome as a potential biomarker for the various neurodegenerative disorders is also under investigation.
The global Diagnostic Exosome Biomarker market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Diagnostic Exosome Biomarker, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diagnostic Exosome Biomarker.
Report Scope
The Diagnostic Exosome Biomarker market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Diagnostic Exosome Biomarker market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diagnostic Exosome Biomarker companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
101Bio
AMS Biotechnology
BioRegenerative Sciences
Cell Guidance Systems
Codiak BioSciences
Evomic Science
ExoCyte Therapeutics
Bio-Techne
Exovita biosciences
Immune Therapy Holdings
Lonza
Norgen Biotek
ReNeuron Group
Therapeutic Solutions International
Segment by Type
Membrane-bound Proteins
Soluble Proteins
Noncoding RNA
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Diagnostic Exosome Biomarker companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diagnostic Exosome Biomarker Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Membrane-bound Proteins
1.2.3 Soluble Proteins
1.2.4 Noncoding RNA
1.2.5 Others
1.3 Market by Application
1.3.1 Global Diagnostic Exosome Biomarker Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Diagnostic Exosome Biomarker Market Perspective (2019-2030)
2.2 Diagnostic Exosome Biomarker Growth Trends by Region
2.2.1 Global Diagnostic Exosome Biomarker Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Diagnostic Exosome Biomarker Historic Market Size by Region (2019-2024)
2.2.3 Diagnostic Exosome Biomarker Forecasted Market Size by Region (2025-2030)
2.3 Diagnostic Exosome Biomarker Market Dynamics
2.3.1 Diagnostic Exosome Biomarker Industry Trends
2.3.2 Diagnostic Exosome Biomarker Market Drivers
2.3.3 Diagnostic Exosome Biomarker Market Challenges
2.3.4 Diagnostic Exosome Biomarker Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diagnostic Exosome Biomarker Players by Revenue
3.1.1 Global Top Diagnostic Exosome Biomarker Players by Revenue (2019-2024)
3.1.2 Global Diagnostic Exosome Biomarker Revenue Market Share by Players (2019-2024)
3.2 Global Diagnostic Exosome Biomarker Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Diagnostic Exosome Biomarker Revenue
3.4 Global Diagnostic Exosome Biomarker Market Concentration Ratio
3.4.1 Global Diagnostic Exosome Biomarker Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diagnostic Exosome Biomarker Revenue in 2023
3.5 Diagnostic Exosome Biomarker Key Players Head office and Area Served
3.6 Key Players Diagnostic Exosome Biomarker Product Solution and Service
3.7 Date of Enter into Diagnostic Exosome Biomarker Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Diagnostic Exosome Biomarker Breakdown Data by Type
4.1 Global Diagnostic Exosome Biomarker Historic Market Size by Type (2019-2024)
4.2 Global Diagnostic Exosome Biomarker Forecasted Market Size by Type (2025-2030)
5 Diagnostic Exosome Biomarker Breakdown Data by Application
5.1 Global Diagnostic Exosome Biomarker Historic Market Size by Application (2019-2024)
5.2 Global Diagnostic Exosome Biomarker Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Diagnostic Exosome Biomarker Market Size (2019-2030)
6.2 North America Diagnostic Exosome Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Diagnostic Exosome Biomarker Market Size by Country (2019-2024)
6.4 North America Diagnostic Exosome Biomarker Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Diagnostic Exosome Biomarker Market Size (2019-2030)
7.2 Europe Diagnostic Exosome Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Diagnostic Exosome Biomarker Market Size by Country (2019-2024)
7.4 Europe Diagnostic Exosome Biomarker Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Diagnostic Exosome Biomarker Market Size (2019-2030)
8.2 Asia-Pacific Diagnostic Exosome Biomarker Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Diagnostic Exosome Biomarker Market Size by Region (2019-2024)
8.4 Asia-Pacific Diagnostic Exosome Biomarker Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Diagnostic Exosome Biomarker Market Size (2019-2030)
9.2 Latin America Diagnostic Exosome Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Diagnostic Exosome Biomarker Market Size by Country (2019-2024)
9.4 Latin America Diagnostic Exosome Biomarker Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Diagnostic Exosome Biomarker Market Size (2019-2030)
10.2 Middle East & Africa Diagnostic Exosome Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Diagnostic Exosome Biomarker Market Size by Country (2019-2024)
10.4 Middle East & Africa Diagnostic Exosome Biomarker Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 101Bio
11.1.1 101Bio Company Detail
11.1.2 101Bio Business Overview
11.1.3 101Bio Diagnostic Exosome Biomarker Introduction
11.1.4 101Bio Revenue in Diagnostic Exosome Biomarker Business (2019-2024)
11.1.5 101Bio Recent Development
11.2 AMS Biotechnology
11.2.1 AMS Biotechnology Company Detail
11.2.2 AMS Biotechnology Business Overview
11.2.3 AMS Biotechnology Diagnostic Exosome Biomarker Introduction
11.2.4 AMS Biotechnology Revenue in Diagnostic Exosome Biomarker Business (2019-2024)
11.2.5 AMS Biotechnology Recent Development
11.3 BioRegenerative Sciences
11.3.1 BioRegenerative Sciences Company Detail
11.3.2 BioRegenerative Sciences Business Overview
11.3.3 BioRegenerative Sciences Diagnostic Exosome Biomarker Introduction
11.3.4 BioRegenerative Sciences Revenue in Diagnostic Exosome Biomarker Business (2019-2024)
11.3.5 BioRegenerative Sciences Recent Development
11.4 Cell Guidance Systems
11.4.1 Cell Guidance Systems Company Detail
11.4.2 Cell Guidance Systems Business Overview
11.4.3 Cell Guidance Systems Diagnostic Exosome Biomarker Introduction
11.4.4 Cell Guidance Systems Revenue in Diagnostic Exosome Biomarker Business (2019-2024)
11.4.5 Cell Guidance Systems Recent Development
11.5 Codiak BioSciences
11.5.1 Codiak BioSciences Company Detail
11.5.2 Codiak BioSciences Business Overview
11.5.3 Codiak BioSciences Diagnostic Exosome Biomarker Introduction
11.5.4 Codiak BioSciences Revenue in Diagnostic Exosome Biomarker Business (2019-2024)
11.5.5 Codiak BioSciences Recent Development
11.6 Evomic Science
11.6.1 Evomic Science Company Detail
11.6.2 Evomic Science Business Overview
11.6.3 Evomic Science Diagnostic Exosome Biomarker Introduction
11.6.4 Evomic Science Revenue in Diagnostic Exosome Biomarker Business (2019-2024)
11.6.5 Evomic Science Recent Development
11.7 ExoCyte Therapeutics
11.7.1 ExoCyte Therapeutics Company Detail
11.7.2 ExoCyte Therapeutics Business Overview
11.7.3 ExoCyte Therapeutics Diagnostic Exosome Biomarker Introduction
11.7.4 ExoCyte Therapeutics Revenue in Diagnostic Exosome Biomarker Business (2019-2024)
11.7.5 ExoCyte Therapeutics Recent Development
11.8 Bio-Techne
11.8.1 Bio-Techne Company Detail
11.8.2 Bio-Techne Business Overview
11.8.3 Bio-Techne Diagnostic Exosome Biomarker Introduction
11.8.4 Bio-Techne Revenue in Diagnostic Exosome Biomarker Business (2019-2024)
11.8.5 Bio-Techne Recent Development
11.9 Exovita biosciences
11.9.1 Exovita biosciences Company Detail
11.9.2 Exovita biosciences Business Overview
11.9.3 Exovita biosciences Diagnostic Exosome Biomarker Introduction
11.9.4 Exovita biosciences Revenue in Diagnostic Exosome Biomarker Business (2019-2024)
11.9.5 Exovita biosciences Recent Development
11.10 Immune Therapy Holdings
11.10.1 Immune Therapy Holdings Company Detail
11.10.2 Immune Therapy Holdings Business Overview
11.10.3 Immune Therapy Holdings Diagnostic Exosome Biomarker Introduction
11.10.4 Immune Therapy Holdings Revenue in Diagnostic Exosome Biomarker Business (2019-2024)
11.10.5 Immune Therapy Holdings Recent Development
11.11 Lonza
11.11.1 Lonza Company Detail
11.11.2 Lonza Business Overview
11.11.3 Lonza Diagnostic Exosome Biomarker Introduction
11.11.4 Lonza Revenue in Diagnostic Exosome Biomarker Business (2019-2024)
11.11.5 Lonza Recent Development
11.12 Norgen Biotek
11.12.1 Norgen Biotek Company Detail
11.12.2 Norgen Biotek Business Overview
11.12.3 Norgen Biotek Diagnostic Exosome Biomarker Introduction
11.12.4 Norgen Biotek Revenue in Diagnostic Exosome Biomarker Business (2019-2024)
11.12.5 Norgen Biotek Recent Development
11.13 ReNeuron Group
11.13.1 ReNeuron Group Company Detail
11.13.2 ReNeuron Group Business Overview
11.13.3 ReNeuron Group Diagnostic Exosome Biomarker Introduction
11.13.4 ReNeuron Group Revenue in Diagnostic Exosome Biomarker Business (2019-2024)
11.13.5 ReNeuron Group Recent Development
11.14 Therapeutic Solutions International
11.14.1 Therapeutic Solutions International Company Detail
11.14.2 Therapeutic Solutions International Business Overview
11.14.3 Therapeutic Solutions International Diagnostic Exosome Biomarker Introduction
11.14.4 Therapeutic Solutions International Revenue in Diagnostic Exosome Biomarker Business (2019-2024)
11.14.5 Therapeutic Solutions International Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Diagnostic Exosome Biomarker Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Membrane-bound Proteins
Table 3. Key Players of Soluble Proteins
Table 4. Key Players of Noncoding RNA
Table 5. Key Players of Others
Table 6. Global Diagnostic Exosome Biomarker Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Diagnostic Exosome Biomarker Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Diagnostic Exosome Biomarker Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Diagnostic Exosome Biomarker Market Share by Region (2019-2024)
Table 10. Global Diagnostic Exosome Biomarker Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Diagnostic Exosome Biomarker Market Share by Region (2025-2030)
Table 12. Diagnostic Exosome Biomarker Market Trends
Table 13. Diagnostic Exosome Biomarker Market Drivers
Table 14. Diagnostic Exosome Biomarker Market Challenges
Table 15. Diagnostic Exosome Biomarker Market Restraints
Table 16. Global Diagnostic Exosome Biomarker Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Diagnostic Exosome Biomarker Market Share by Players (2019-2024)
Table 18. Global Top Diagnostic Exosome Biomarker Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diagnostic Exosome Biomarker as of 2023)
Table 19. Ranking of Global Top Diagnostic Exosome Biomarker Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Diagnostic Exosome Biomarker Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Diagnostic Exosome Biomarker Product Solution and Service
Table 23. Date of Enter into Diagnostic Exosome Biomarker Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Diagnostic Exosome Biomarker Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Diagnostic Exosome Biomarker Revenue Market Share by Type (2019-2024)
Table 27. Global Diagnostic Exosome Biomarker Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Diagnostic Exosome Biomarker Revenue Market Share by Type (2025-2030)
Table 29. Global Diagnostic Exosome Biomarker Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Diagnostic Exosome Biomarker Revenue Market Share by Application (2019-2024)
Table 31. Global Diagnostic Exosome Biomarker Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Diagnostic Exosome Biomarker Revenue Market Share by Application (2025-2030)
Table 33. North America Diagnostic Exosome Biomarker Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Diagnostic Exosome Biomarker Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Diagnostic Exosome Biomarker Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Diagnostic Exosome Biomarker Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Diagnostic Exosome Biomarker Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Diagnostic Exosome Biomarker Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Diagnostic Exosome Biomarker Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Diagnostic Exosome Biomarker Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Diagnostic Exosome Biomarker Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Diagnostic Exosome Biomarker Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Diagnostic Exosome Biomarker Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Diagnostic Exosome Biomarker Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Diagnostic Exosome Biomarker Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Diagnostic Exosome Biomarker Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Diagnostic Exosome Biomarker Market Size by Country (2025-2030) & (US$ Million)
Table 48. 101Bio Company Detail
Table 49. 101Bio Business Overview
Table 50. 101Bio Diagnostic Exosome Biomarker Product
Table 51. 101Bio Revenue in Diagnostic Exosome Biomarker Business (2019-2024) & (US$ Million)
Table 52. 101Bio Recent Development
Table 53. AMS Biotechnology Company Detail
Table 54. AMS Biotechnology Business Overview
Table 55. AMS Biotechnology Diagnostic Exosome Biomarker Product
Table 56. AMS Biotechnology Revenue in Diagnostic Exosome Biomarker Business (2019-2024) & (US$ Million)
Table 57. AMS Biotechnology Recent Development
Table 58. BioRegenerative Sciences Company Detail
Table 59. BioRegenerative Sciences Business Overview
Table 60. BioRegenerative Sciences Diagnostic Exosome Biomarker Product
Table 61. BioRegenerative Sciences Revenue in Diagnostic Exosome Biomarker Business (2019-2024) & (US$ Million)
Table 62. BioRegenerative Sciences Recent Development
Table 63. Cell Guidance Systems Company Detail
Table 64. Cell Guidance Systems Business Overview
Table 65. Cell Guidance Systems Diagnostic Exosome Biomarker Product
Table 66. Cell Guidance Systems Revenue in Diagnostic Exosome Biomarker Business (2019-2024) & (US$ Million)
Table 67. Cell Guidance Systems Recent Development
Table 68. Codiak BioSciences Company Detail
Table 69. Codiak BioSciences Business Overview
Table 70. Codiak BioSciences Diagnostic Exosome Biomarker Product
Table 71. Codiak BioSciences Revenue in Diagnostic Exosome Biomarker Business (2019-2024) & (US$ Million)
Table 72. Codiak BioSciences Recent Development
Table 73. Evomic Science Company Detail
Table 74. Evomic Science Business Overview
Table 75. Evomic Science Diagnostic Exosome Biomarker Product
Table 76. Evomic Science Revenue in Diagnostic Exosome Biomarker Business (2019-2024) & (US$ Million)
Table 77. Evomic Science Recent Development
Table 78. ExoCyte Therapeutics Company Detail
Table 79. ExoCyte Therapeutics Business Overview
Table 80. ExoCyte Therapeutics Diagnostic Exosome Biomarker Product
Table 81. ExoCyte Therapeutics Revenue in Diagnostic Exosome Biomarker Business (2019-2024) & (US$ Million)
Table 82. ExoCyte Therapeutics Recent Development
Table 83. Bio-Techne Company Detail
Table 84. Bio-Techne Business Overview
Table 85. Bio-Techne Diagnostic Exosome Biomarker Product
Table 86. Bio-Techne Revenue in Diagnostic Exosome Biomarker Business (2019-2024) & (US$ Million)
Table 87. Bio-Techne Recent Development
Table 88. Exovita biosciences Company Detail
Table 89. Exovita biosciences Business Overview
Table 90. Exovita biosciences Diagnostic Exosome Biomarker Product
Table 91. Exovita biosciences Revenue in Diagnostic Exosome Biomarker Business (2019-2024) & (US$ Million)
Table 92. Exovita biosciences Recent Development
Table 93. Immune Therapy Holdings Company Detail
Table 94. Immune Therapy Holdings Business Overview
Table 95. Immune Therapy Holdings Diagnostic Exosome Biomarker Product
Table 96. Immune Therapy Holdings Revenue in Diagnostic Exosome Biomarker Business (2019-2024) & (US$ Million)
Table 97. Immune Therapy Holdings Recent Development
Table 98. Lonza Company Detail
Table 99. Lonza Business Overview
Table 100. Lonza Diagnostic Exosome Biomarker Product
Table 101. Lonza Revenue in Diagnostic Exosome Biomarker Business (2019-2024) & (US$ Million)
Table 102. Lonza Recent Development
Table 103. Norgen Biotek Company Detail
Table 104. Norgen Biotek Business Overview
Table 105. Norgen Biotek Diagnostic Exosome Biomarker Product
Table 106. Norgen Biotek Revenue in Diagnostic Exosome Biomarker Business (2019-2024) & (US$ Million)
Table 107. Norgen Biotek Recent Development
Table 108. ReNeuron Group Company Detail
Table 109. ReNeuron Group Business Overview
Table 110. ReNeuron Group Diagnostic Exosome Biomarker Product
Table 111. ReNeuron Group Revenue in Diagnostic Exosome Biomarker Business (2019-2024) & (US$ Million)
Table 112. ReNeuron Group Recent Development
Table 113. Therapeutic Solutions International Company Detail
Table 114. Therapeutic Solutions International Business Overview
Table 115. Therapeutic Solutions International Diagnostic Exosome Biomarker Product
Table 116. Therapeutic Solutions International Revenue in Diagnostic Exosome Biomarker Business (2019-2024) & (US$ Million)
Table 117. Therapeutic Solutions International Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Diagnostic Exosome Biomarker Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Diagnostic Exosome Biomarker Market Share by Type: 2023 VS 2030
Figure 3. Membrane-bound Proteins Features
Figure 4. Soluble Proteins Features
Figure 5. Noncoding RNA Features
Figure 6. Others Features
Figure 7. Global Diagnostic Exosome Biomarker Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Diagnostic Exosome Biomarker Market Share by Application: 2023 VS 2030
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Ambulatory Surgical Centers Case Studies
Figure 12. Diagnostic Exosome Biomarker Report Years Considered
Figure 13. Global Diagnostic Exosome Biomarker Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Diagnostic Exosome Biomarker Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Diagnostic Exosome Biomarker Market Share by Region: 2023 VS 2030
Figure 16. Global Diagnostic Exosome Biomarker Market Share by Players in 2023
Figure 17. Global Top Diagnostic Exosome Biomarker Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diagnostic Exosome Biomarker as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Diagnostic Exosome Biomarker Revenue in 2023
Figure 19. North America Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Diagnostic Exosome Biomarker Market Share by Country (2019-2030)
Figure 21. United States Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Diagnostic Exosome Biomarker Market Share by Country (2019-2030)
Figure 25. Germany Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Diagnostic Exosome Biomarker Market Share by Region (2019-2030)
Figure 33. China Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Diagnostic Exosome Biomarker Market Share by Country (2019-2030)
Figure 41. Mexico Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Diagnostic Exosome Biomarker Market Share by Country (2019-2030)
Figure 45. Turkey Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Diagnostic Exosome Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. 101Bio Revenue Growth Rate in Diagnostic Exosome Biomarker Business (2019-2024)
Figure 48. AMS Biotechnology Revenue Growth Rate in Diagnostic Exosome Biomarker Business (2019-2024)
Figure 49. BioRegenerative Sciences Revenue Growth Rate in Diagnostic Exosome Biomarker Business (2019-2024)
Figure 50. Cell Guidance Systems Revenue Growth Rate in Diagnostic Exosome Biomarker Business (2019-2024)
Figure 51. Codiak BioSciences Revenue Growth Rate in Diagnostic Exosome Biomarker Business (2019-2024)
Figure 52. Evomic Science Revenue Growth Rate in Diagnostic Exosome Biomarker Business (2019-2024)
Figure 53. ExoCyte Therapeutics Revenue Growth Rate in Diagnostic Exosome Biomarker Business (2019-2024)
Figure 54. Bio-Techne Revenue Growth Rate in Diagnostic Exosome Biomarker Business (2019-2024)
Figure 55. Exovita biosciences Revenue Growth Rate in Diagnostic Exosome Biomarker Business (2019-2024)
Figure 56. Immune Therapy Holdings Revenue Growth Rate in Diagnostic Exosome Biomarker Business (2019-2024)
Figure 57. Lonza Revenue Growth Rate in Diagnostic Exosome Biomarker Business (2019-2024)
Figure 58. Norgen Biotek Revenue Growth Rate in Diagnostic Exosome Biomarker Business (2019-2024)
Figure 59. ReNeuron Group Revenue Growth Rate in Diagnostic Exosome Biomarker Business (2019-2024)
Figure 60. Therapeutic Solutions International Revenue Growth Rate in Diagnostic Exosome Biomarker Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
